ArticleFrontiers in pharmacology2026
Pathway-based molecular subtyping identifies LAMP5 as an EMT-associated prognostic target in colorectal cancer.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Colorectal cancer (CRC) is a highly heterogeneous malignancy with substantial variability in clinical outcomes. Although established molecular classification systems have improved CRC stratification, pathway-level subtyping remains underexplored. A framework integrating pathway-based molecular subtype discovery, multi-cohort validation, single-cell projection, and mechanistic target identification is still lacking. Methods: Transcriptomic data from TCGA CRC samples were transformed into pathway activity profiles using gene set variation analysis (GSVA), followed by consensus clustering to define pathway-based molecular subtypes. Nearest template prediction (NTP) was applied across 17 independent cohorts to validate subtype robustness. Three CRC single-cell RNA-seq datasets were integrated and analyzed using the single-cell phenotype-associated subpopulation identifier (scPAS) to map subtype-associated signals at cellular resolution. Multi-cohort Cox regression identified prognostic genes, and LAMP5 was further assessed through clinicopathological correlation, pathway enrichment analyses, and experimental validation Results: Four pathway-based molecular subtypes were identified, among which C4 had the worst prognosis. The subtype classification was reproducible across 17 external cohorts. Single-cell analysis suggested that the aggressive subtype-associated phenotype could be projected onto distinct cell populations. LAMP5 emerged as the most consistent unfavorable prognostic gene across cohorts and was associated with advanced clinicopathological features. Functional analyses linked LAMP5 to TGFβ signaling, epithelial-mesenchymal transition (EMT), angiogenesis, invasion, and metastasis. Experimental results supported the pro-tumorigenic role of LAMP5 in CRC. Conclusion: This study establishes a pathway-based molecular classification framework for CRC and identifies LAMP5 as a robust prognostic biomarker and candidate therapeutic target associated with the EMT pathway.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.